Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma clinical trial (NCT03095079). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to standard options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma clinical trial (NCT03095079). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from the treatments involved?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma clinical trial (NCT03095079). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma clinical trial (NCT03095079). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any other treatments I should consider alongside this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma clinical trial (NCT03095079). Contact the study team or your healthcare provider for specific answers.

What this study is about